CHOLESTEROL - gallbladder and biliary tract

Patients who have high cholesterol levels in their bile tend to form small crystals, which eventually develop into gallstones which can lead to problems such as cholecystitis (in which the gallbladder becomes inflamed because the cystic duct is blocked) or cholangitis (in which the common bile duct becomes obstructed).    

BioMonde's response!

The Global

Burden of Gallbladder disease

The highest prevalence of gallbladder disease occurs in the USA and Western Europe. It is estimated that 17 million people in the USA , 15 million people in Western Europe, and 2.7 million people in South Africa have gallstones.  The American Cancer Society estimates that about 9,250 new cases of gallbladder cancer and bile duct cancer were diagnosed in 2007 in the United States. About 3,250 people died of these cancers in 2007.

 

Problems associated with gall bladder removal

surgery is invasive;
infection;

bile duct damage;

bile is released continuously;

bowel problems.

 

Gallbladder

 

Gallstones in Gallbladder  

    

  

Development of a optimized, safe, effective and affordable class of novel anti-inflammatory choleretic umbelliferone (4-meythylumbellierone - 4MU) derivatives.

• a therapy in the treatment of gallstones;
• a preventive therapy against gallstones;
• a therapy in the treatment of cholangitis;
• a therapy in the treatment of cholecystitis;
• a therapy in the treatment of pancreatitis caused by gallstones;
• a therapy to alleviate jaundice;
• a adjunct to cholesterol lowering drugs.

BioMonde is focused on the prevention and treatment of gallbladder disease, and progression to gallbladder cancer. Gallstones, inflammation of the bile ducts, the gallbladder and the pancreas, are common problems resulting from cholesterol and a bad diet. The standard treatment for gallbladder disease is surgical removal. When gallstones form, they block the ducts and prevent bile from being released into the digestive system, which leads to inflammation and jaundice. The anti-inflammatory action of umbelliferone derivatives (4-meythylumbellierone) reduce inflammation releasing the gallstones, which are flushed through the digestive system.  Consequently, BioMonde's approach means that less patients have to undergo invasive surgery to remove the gallbladder.

REFERENCE MATERIAL

Published and  Peer Reviewed Studies click-here

View our product pipeline click-here

Products containing umbelliferone derivatives (4-Methylumbelliferone) click-here

HEPARVIT™ ProGALL

Medical research...........

Indicates that umbelliferone derivatives (4-meythylumbellierone) administered as a preventive or management therapy for gall bladder disorders:

• reduce inflammation of the gall bladder and bile ducts;
• reduces inflammation of sphincter of oddi;
• increase the livers production of bile which uses more cholesterol;
• alleviates jaundice;
• reduces the liver toxic side effects associated with cholesterol lowering drugs.